By providing light on possible TCM-based inhibitors targeting PSAT1, this publication seeks to further the knowledge in the area and open the door for additional preclinical and clinical research in the search for better treatment approaches for early-stage ovarian cancer [14,15]. The gene discussed is PSAT1; the disease is ovarian carcinoma.